What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Endocrinology
The scientist’s investigation covers issues in Internal medicine, Pharmacology, Hemodynamics, Endocrinology and Anesthesia.
The various areas that Hans-Georg Eichler examines in his Internal medicine study include Number needed to treat and Cardiology.
The study incorporates disciplines such as Alternative medicine, Clinical trial, Reimbursement and Immunology in addition to Pharmacology.
His Hemodynamics research is multidisciplinary, relying on both Blood flow, Intraocular pressure, Timolol and Retinal, Fundus.
His Endocrinology study which covers Platelet that intersects with Aspirin.
In his study, Hydroxyethyl starch, Perfusion, Fibrinolysis and Albumin is strongly linked to Crossover study, which falls under the umbrella field of Anesthesia.
His most cited work include:
- bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. (477 citations)
- Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications (255 citations)
- Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. (219 citations)
What are the main themes of his work throughout his whole career to date?
Hans-Georg Eichler mainly investigates Internal medicine, Endocrinology, Pharmacology, Anesthesia and Hemodynamics.
His studies link Cardiology with Internal medicine.
Hans-Georg Eichler interconnects Platelet and Vein in the investigation of issues within Endocrinology.
His Pharmacology research integrates issues from Anticoagulant, Alternative medicine and Immunology.
His biological study spans a wide range of topics, including Placebo and Crossover study.
His work carried out in the field of Hemodynamics brings together such families of science as Blood flow, Ophthalmology, Blood pressure, Fundus and Vasodilation.
He most often published in these fields:
- Internal medicine (34.80%)
- Endocrinology (29.67%)
- Pharmacology (23.44%)
What were the highlights of his more recent work (between 2012-2021)?
- MEDLINE (7.69%)
- Clinical trial (7.33%)
- Risk analysis (4.76%)
In recent papers he was focusing on the following fields of study:
Hans-Georg Eichler mainly focuses on MEDLINE, Clinical trial, Risk analysis, Agency and Public relations.
His study in MEDLINE is interdisciplinary in nature, drawing from both Health technology, Data mining, Randomized controlled trial, Marketing authorization and Harm.
Hans-Georg Eichler has researched Clinical trial in several fields, including Psychological intervention, Treatment outcome, Intensive care medicine, Alternative medicine and Pharmacology.
When carried out as part of a general Pharmacology research project, his work on Pharmacokinetics is frequently linked to work in Information source, therefore connecting diverse disciplines of study.
The concepts of his Risk analysis study are interwoven with issues in Clinical study design, Drug pricing, Drug development and Licensure.
His research in Public relations intersects with topics in Government, Private sector and Reflection.
Between 2012 and 2021, his most popular works were:
- The risks of risk aversion in drug regulation (66 citations)
- Transparency and the European Medicines Agency — Sharing of Clinical Trial Data (58 citations)
- Access to Patient-Level Trial Data — A Boon to Drug Developers (55 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His main research concerns MEDLINE, Clinical trial, Agency, Pharmacology and Drug.
His MEDLINE research incorporates elements of Health technology, Data mining, Risk analysis, Marketing authorization and Harm.
His work deals with themes such as Alternative medicine, Transparency and Randomized controlled trial, which intersect with Clinical trial.
His Randomized controlled trial research incorporates themes from Cost–benefit analysis, Treatment outcome and Medical physics.
His Pharmacology research is multidisciplinary, incorporating elements of International trade and Drug discovery.
His work on Drug approval as part of general Drug study is frequently linked to Public economics, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
